Evidence map›Paper›PMID 27385709›Full record

ArticleJournal of clinical microbiology2016

Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes.

Emma Thomson, Camilla L C Ip, Anjna Badhan, Mette T Christiansen, Walt Adamson, M Azim Ansari, David Bibby, Judith Breuer, Anthony Brown, Rory Bowden and 18 more

Abstract readComparative StudyEvaluation StudyMulticenter Study
In one paragraph

Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed.

  1. Review
  2. Enrichment techniques for clinical metagenomics.Frontiers in cellular and infection microbiology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Emma ThomsonMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Camilla L C IpOxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Anjna BadhanVirus Reference Department, Public Health England, London, United Kingdom.
Mette T ChristiansenUniversity College London (UCL), Division of Infection and Immunity, London, United Kingdom.
Walt AdamsonMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
M Azim AnsariNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
David BibbyVirus Reference Department, Public Health England, London, United Kingdom.ORCID 0000-0002-8458-9662
Judith BreuerUniversity College London (UCL), Division of Infection and Immunity, London, United Kingdom.
Anthony BrownNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Rory BowdenOxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Josie BryantUniversity College London (UCL), Division of Infection and Immunity, London, United Kingdom.ORCID 0000-0002-0149-5768
David BonsallNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Ana Da Silva FilipeMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Chris HindsMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Emma HudsonNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Paul KlenermanNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Kieren LythgowVirus Reference Department, Public Health England, London, United Kingdom.
Jean L MbisaVirus Reference Department, Public Health England, London, United Kingdom.
John McLauchlanMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Richard MyersVirus Reference Department, Public Health England, London, United Kingdom.
Paolo PiazzaOxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Sunando RoyUniversity College London (UCL), Division of Infection and Immunity, London, United Kingdom.
Amy TrebesOxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Vattipally B SreenuMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Jeroen WitteveldtRoslin Institute, University of Edinburgh, Edinburgh, United Kingdom.
STOP-HCV Consortium
Eleanor BarnesNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom ellie.barnes@ndm.ox.ac.uk.
Peter SimmondsNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom.

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
Department of Health 14/02/17Medical Research Council G0801822Medical Research Council MC_EX_UU_G1000717Medical Research Council MC_UU_12014/1Medical Research Council MC_UU_12014/12Medical Research Council MR/K010239/1Medical Research Council MR/K01532X/1MRF_ C0365NIAID NIH HHS U19 AI082630Wellcome Trust 091663Wellcome Trust 109965/Z/15/Z
6 · The paper itself

Abstract

Affordable next-generation sequencing (NGS) technologies for hepatitis C virus (HCV) may potentially identify both viral genotype and resistance genetic motifs in the era of directly acting antiviral (DAA) therapies. This study compared the ability of high-throughput NGS methods to generate full-length, deep, HCV sequence data sets and evaluated their utility for diagnostics and clinical assessment. NGS methods using (i) unselected HCV RNA (metagenomics), (ii) preenrichment of HCV RNA by probe capture, and (iii) HCV preamplification by PCR implemented in four United Kingdom centers were compared. Metrics of sequence coverage and depth, quasispecies diversity, and detection of DAA resistance-associated variants (RAVs), mixed HCV genotypes, and other coinfections were compared using a panel of samples with different viral loads, genotypes, and mixed HCV genotypes/subtypes [geno(sub)types]. Each NGS method generated near-complete genome sequences from more than 90% of samples. Enrichment methods and PCR preamplification generated greater sequence depth and were more effective for samples with low viral loads. All NGS methodologies accurately identified mixed HCV genotype infections. Consensus sequences generated by different NGS methods were generally concordant, and majority RAVs were consistently detected. However, methods differed in their ability to detect minor populations of RAVs. Metagenomic methods identified human pegivirus coinfections. NGS provided a rapid, inexpensive method for generating whole HCV genomes to define infecting genotypes, RAVs, comprehensive viral strain analysis, and quasispecies diversity. Enrichment methods are particularly suited for high-throughput analysis while providing the genotype and information on potential DAA resistance.

Indexed as

Genome, ViralGenotypeDrug Resistance, ViralHepacivirusHepatitis CHigh-Throughput Nucleotide SequencingHumansSequence Analysis, DNAUnited Kingdom

Identifiers

PMID27385709
PMCPMC5035407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.